Promoting Tolerance to Peanut in High-Risk Children

Principal Investigator

Gideon Lack | Kings College London | London, England

Locations

King's College London, St. Thomas Hospital | London, England

Study Code

ITN032AD

Study Status

Complete

Abstract

‍

The prevalence of peanut allergy has doubled over the past 10 years in countries that advocate avoidance of peanuts during pregnancy, lactation and infancy. Peanut allergy now affects approximately 1.5% of young children. There are 2 main explanations for this failure to prevent peanut allergies through avoidance measures: 1. Sensitisation to food allergens may not occur through oral exposure, but rather through other routes such as topical cutaneous exposure, and 2. Early oral exposure may be required to prevent the development of peanut allergy through oral tolerance induction. UK and US guidelines had previously discouraged oral exposure during pregnancy, breastfeeding and infancy. These guidelines may have promoted allergic sensitisation by creating a situation where there is environmental cutaneous exposure in the absence of early oral tolerance induction. This imbalance in the routes of allergen presentation may favour the development of allergic sensitisation.

The primary aim of our study is to determine which is the best strategy for reducing peanut allergy, early high dose consumption of peanut protein or avoidance. Secondary aims are to compare the development of sensitisation to peanuts, the development of tree nut allergy at age 5, sensitisation to control allergens (house dust mite and egg) and immunological assays.

Of the children who avoided peanut, 17% developed peanut allergy by the age of 5 years. Remarkably, only 3% of the children who were randomized to eating the peanut snack developed allergy by age 5. Therefore, in high-risk infants, sustained consumption of peanut beginning in the first 11 months of life was highly effective in preventing the development of peanut allergy.

This randomized parallel group study enrolled high risk infants. Half the children were randomised to early high dose consumption of peanut snack between age 4-11 months and the other half were randomized to complete dietary peanut avoidance. All 640 study participants were enrolled as of May 2009.

Immunological assays will focus on alterations in the function of peanut-specific T cells (cytokine production, precursor cell frequency), the development of regulatory T cells subsets, the importance of IgE dependent facilitated antigen presentation and the development of IgG4 as a “blocking antibody.” Peptide specific IgE and IgG epitopes in the different tolerant and allergic states will also be studied. This will allow us to address both the clinical and immunological specificity of oral tolerance induction, study the underlying mechanisms of oral tolerance and provide a new strategy to prevent allergic disease.

Qualification

[Clinicaltrials.gov][Study Website]

Articles

Logan K, Bahnson HT, Ylescupidez A, Beyer K, Bellach J, Campbell DE, Craven J, Du Toit G, Clare Mills EN, Perkin MR, Roberts G, van Ree R, Lack G (2023). Early introduction of peanut reduces peanut allergy across risk groups in pooled and causal inference analyses. Allergy, 78 (5), 1307-1318.

DOI:

http://dx.doi.org/10.1111/all.15597

,‎

PMID:

36435990

,‎

PMCID:

,‎